India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention
This article was originally published in PharmAsia News
Executive Summary
Major Indian drug makers, including Elder Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, Ranbaxy Laboratories and Unichem Laboratories spend as much as 10% of their generic production costs on preventing counterfeits.